Skip to main content
SpringerLink
Log in

Transplantation for Multiple Myeloma

  • Chapter
  • First Online:
Plasma Cell Dyscrasias

Part of the book series: Cancer Treatment and Research ((CTAR,volume 169))

  • 2493 Accesses

Abstract

Multiple myeloma is a disorder characterized by accumulation of malignant plasma cells in the bone marrow, hypercalcemia, monoclonal protein, and end organ damage. Recently newer generation proteosome inhibitors, monoclonal antibodies and novel agents have been approved by FDA, which is undoubtedly increasing life expectancy of the patients. However, hematopoietic stem cell transplantation still remains the cornerstone of the treatment. In this chapter, we are discussing the autologous stem cell transplant, allogeneic stem cell transplant and total therapy trials with outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Stewart AK, Bergsagel PL, Greipp PR, Dispenzieri A, Gertz MA, Hayman SR et al (2007) A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia 21(3):529–534

    Article  CAS  PubMed  Google Scholar 

  2. Zhan F, Hardin J, Kordsmeier B, Bumm K, Zheng M, Tian E et al (2002) Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 99(5):1745–1757

    Article  CAS  PubMed  Google Scholar 

  3. Fermand JP, Ravaud P, Chevret S, Divine M, Leblond V, Belanger C et al (1998) High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 92(9):3131–3136

    CAS  PubMed  Google Scholar 

  4. Bergsagel DE, Ross SW, Baker DT (1962) Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma. V. 1-Aminocyclopentanecarboxylic acid (NSC-1026). Cancer Chemother Rep Part 1 21:101–106

    Google Scholar 

  5. Alexanian R, Haut A, Khan AU, Lane M, McKelvey EM, Migliore PJ et al (1969) Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA 208(9):1680–1685

    Article  CAS  PubMed  Google Scholar 

  6. Gay F, Hajek R, Diramondo F et al (2013) Cyclophosphamidelenalidomide-dexamethasone vs autologous transplant in newly diagnosed myeloma: a phase 3 trial. Clin Lymphoma Myeloma Leuk 13(suppl 1):S40

    Google Scholar 

  7. Boccadoro M, Cavallo F, Gay F, Di Raimondo F, Nagler A, Montefusco V (2013) Melphalan/prednisone/lenalidomide (MPR) versus high-dose melphalan and autologous transplantation (MEL200) plus lenalidomide maintenance or no maintenance in newly diagnosed multiple myeloma (MM) patients. J Clin Oncol 31(suppl):8509

    Google Scholar 

  8. Segeren CM, Sonneveld P, van der Holt B, Vellenga E, Croockewit AJ, Verhoef GE et al (2003) Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study. Blood 101(6):2144–2151

    Article  CAS  PubMed  Google Scholar 

  9. Barlogie B, Jagannath S, Desikan KR, Mattox S, Vesole D, Siegel D et al (1999) Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 93(1):55–65

    CAS  PubMed  Google Scholar 

  10. Barlogie B, Alexanian R, Dicke KA, Zagars G, Spitzer G, Jagannath S et al (1987) High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma. Blood 70(3):869–872

    CAS  PubMed  Google Scholar 

  11. Fermand JP, Katsahian S, Divine M, Leblond V, Dreyfus F, Macro M et al (2005) High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol: Official J Am Soc Clin Oncol 23(36):9227–9233

    Article  CAS  Google Scholar 

  12. Blade J, Rosinol L, Sureda A, Ribera JM, Diaz-Mediavilla J, Garcia-Larana J et al (2005) High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood 106(12):3755–3759

    Article  CAS  PubMed  Google Scholar 

  13. Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, Hurd DD et al (2006) Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol: Official J Am Soc Clin Oncol 24(6):929–936

    Article  CAS  Google Scholar 

  14. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF et al (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 335(2):91–97

    Article  CAS  PubMed  Google Scholar 

  15. Rosinol L, Oriol A, Teruel AI, Hernandez D, Lopez-Jimenez J, de la Rubia J et al (2012) Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood 120(8):1589–1596

    Article  CAS  PubMed  Google Scholar 

  16. Berz D, McCormack EM, Winer ES, Colvin GA, Quesenberry PJ (2007) Cryopreservation of hematopoietic stem cells. Am J Hematol 82(6):463–472

    Article  PubMed  PubMed Central  Google Scholar 

  17. Moreau P, Facon T, Attal M, Hulin C, Michallet M, Maloisel F et al (2002) Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood 99(3):731–735

    Article  CAS  PubMed  Google Scholar 

  18. Desikan KR, Tricot G, Dhodapkar M, Fassas A, Siegel D, Vesole DH et al (2000) Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical controls receiving tandem transplants with melphalan alone. Bone Marrow Transplant 25(5):483–487

    Article  CAS  PubMed  Google Scholar 

  19. Blade J, Vesole DH, Gertz M (2003) High-dose therapy in multiple myeloma. Blood 102(10):3469–3470

    Article  CAS  PubMed  Google Scholar 

  20. Barlogie B, Smith L, Alexanian R (1984) Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 310(21):1353–1356

    Article  CAS  PubMed  Google Scholar 

  21. Harousseau JL, Milpied N, Laporte JP, Collombat P, Facon T, Tigaud JD et al (1992) Double-intensive therapy in high-risk multiple myeloma. Blood 79(11):2827–2833

    CAS  PubMed  Google Scholar 

  22. Fermand JP, Levy Y, Gerota J, Benbunan M, Cosset JM, Castaigne S et al (1989) Treatment of aggressive multiple myeloma by high-dose chemotherapy and total body irradiation followed by blood stem cells autologous graft. Blood 73(1):20–23

    CAS  PubMed  Google Scholar 

  23. Barlogie B, Tricot GJ, van Rhee F, Angtuaco E, Walker R, Epstein J et al (2006) Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol 135(2):158–164

    Article  PubMed  Google Scholar 

  24. Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F et al (2006) Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 354(10):1021–1030

    Article  CAS  PubMed  Google Scholar 

  25. Barlogie B, Tricot G, Rasmussen E, Anaissie E, van Rhee F, Zangari M et al (2006) Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies. Blood 107(7):2633–2638

    Article  CAS  PubMed  Google Scholar 

  26. Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG et al (2003) Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 349(26):2495–2502

    Article  CAS  PubMed  Google Scholar 

  27. Cavo M, Tosi P, Zamagni E, Cellini C, Tacchetti P, Patriarca F et al (2007) Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol: Official J Am Soc Clin Oncol 25(17):2434–2441

    Article  Google Scholar 

  28. Fermand JP, Alberti C, Morolleau JP (2003) Single versus tandem high dose therapy (HDT) supported with autlogous blood stem cell (ABSC) transplantation using unselected or CD34- enriched ABSC: results of a two by two designed radomized trial in 230 young aptients with multiple myeloma (MM). Hematol J 4:S59

    Google Scholar 

  29. Goldschmidt H (2005) Single vs double high dose therapy in multiple myeloma: second analysis of the GMMG-HD2 trial. Haematologica 90:38

    Google Scholar 

  30. Cavo M, Cellini C, Zamagni E (2005) Update on high dose therapy—Italian studies. Haematologica 90:39

    Google Scholar 

  31. Vesole DH, Tricot G, Jagannath S, Desikan KR, Siegel D, Bracy D et al (1996) Autotransplants in multiple myeloma: what have we learned? Blood 88(3):838–847

    CAS  PubMed  Google Scholar 

  32. Awan F, Kochuparambil ST, Falconer DE, Cumpston A, Leadmon S, Watkins K et al (2013) Comparable efficacy and lower cost of PBSC mobilization with intermediate-dose cyclophosphamide and G-CSF compared with plerixafor and G-CSF in patients with multiple myeloma treated with novel therapies. Bone Marrow Transplant 48(10):1279–1284

    Article  CAS  PubMed  Google Scholar 

  33. Hosing C, Qazilbash MH, Kebriaei P, Giralt S, Davis MS, Popat U et al (2006) Fixed-dose single agent pegfilgrastim for peripheral blood progenitor cell mobilisation in patients with multiple myeloma. Br J Haematol 133(5):533–537

    Article  CAS  PubMed  Google Scholar 

  34. DiPersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ, Kaufman JL et al (2009) Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 113(23):5720–5726

    CAS  PubMed  Google Scholar 

  35. Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W, Comenzo RL et al (2009) International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia 23(10):1904–1912

    Article  CAS  PubMed  Google Scholar 

  36. Kumar S, Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W et al (2009) Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. Blood 114(9):1729–1735

    Article  CAS  PubMed  Google Scholar 

  37. Palumbo A, Bringhen S, Bruno B, Falcone AP, Liberati AM, Grasso M et al (2010) Melphalan 200 mg/m(2) versus melphalan 100 mg/m(2) in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study. Blood 115(10):1873–1879

    Article  CAS  PubMed  Google Scholar 

  38. Anagnostopoulos A, Aleman A, Ayers G, Donato M, Champlin R, Weber D et al (2004) Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma. Cancer 100(12):2607–2612

    Article  CAS  PubMed  Google Scholar 

  39. Fenk R, Schneider P, Kropff M, Huenerlituerkoglu AN, Steidl U, Aul C et al (2005) High-dose idarubicin, cyclophosphamide and melphalan as conditioning for autologous stem cell transplantation increases treatment-related mortality in patients with multiple myeloma: results of a randomised study. Br J Haematol 130(4):588–594

    Article  CAS  PubMed  Google Scholar 

  40. Badros A, Barlogie B, Siegel E, Roberts J, Langmaid C, Zangari M et al (2001) Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 114(4):822–829

    Article  CAS  PubMed  Google Scholar 

  41. Facon T, Mary JY, Hulin C, Benboubker L, Attal M, Pegourie B et al (2007) Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 370(9594):1209–1218

    Article  CAS  PubMed  Google Scholar 

  42. Schmitz N, Linch DC, Dreger P, Goldstone AH, Boogaerts MA, Ferrant A et al (1996) Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 347(8998):353–357

    Article  CAS  PubMed  Google Scholar 

  43. Ford PA, Grant SJ, Mick R, Keck G (2015) Autologous stem-cell transplantation without hematopoietic support for the treatment of hematologic malignancies in Jehovah’s witnesses. J Clin Oncol: Official J Am Soc Clin Oncol 33(15):1674–1679

    Article  CAS  Google Scholar 

  44. Gertz MA, Ansell SM, Dingli D, Dispenzieri A, Buadi FK, Elliott MA et al (2008) Autologous stem cell transplant in 716 patients with multiple myeloma: low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiative. Mayo Clin Proc 83(10):1131–1138

    Article  PubMed  Google Scholar 

  45. Jones JA, Qazilbash MH, Shih YC, Cantor SB, Cooksley CD, Elting LS (2008) In-hospital complications of autologous hematopoietic stem cell transplantation for lymphoid malignancies: clinical and economic outcomes from the Nationwide Inpatient Sample. Cancer 112(5):1096–1105

    Article  PubMed  Google Scholar 

  46. Bjorkstrand B, Svensson H, Goldschmidt H, Ljungman P, Apperley J, Mandelli F et al (2001) Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: a retrospective registry study from the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 27(5):511–515

    Article  CAS  PubMed  Google Scholar 

  47. Davies FE, Forsyth PD, Rawstron AC, Owen RG, Pratt G, Evans PA et al (2001) The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma. Br J Haematol 112(3):814–819

    Article  CAS  PubMed  Google Scholar 

  48. Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T et al (2012) Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 366(19):1782–1791

    Article  CAS  PubMed  Google Scholar 

  49. Shaughnessy J, Jacobson J, Sawyer J, McCoy J, Fassas A, Zhan F et al (2003) Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression. Blood 101(10):3849–3856

    Article  CAS  PubMed  Google Scholar 

  50. McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG et al (2012) Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 366(19):1770–1781

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K et al (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348(19):1875–1883

    Article  CAS  PubMed  Google Scholar 

  52. Rajkumar SV, Fonseca R, Dispenzieri A, Lacy MQ, Witzig TE, Lust JA et al (2000) Effect of complete response on outcome following autologous stem cell transplantation for myeloma. Bone Marrow Transplant 26(9):979–983

    Article  CAS  PubMed  Google Scholar 

  53. Walker R, Barlogie B, Haessler J, Tricot G, Anaissie E, Shaughnessy JD Jr et al (2007) Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. J Clin Oncol: Official J Am Soc Clin Oncol 25(9):1121–1128

    Article  Google Scholar 

  54. van Rhee F, Bolejack V, Hollmig K, Pineda-Roman M, Anaissie E, Epstein J et al (2007) High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood 110(3):827–832

    Article  PubMed  PubMed Central  Google Scholar 

  55. Haessler J, Shaughnessy JD Jr, Zhan F, Crowley J, Epstein J, van Rhee F et al (2007) Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling. Clin Cancer Res: Official J Am Assoc Cancer Res 13(23):7073–7079

    Article  CAS  Google Scholar 

  56. Rawstron AC, Gregory WM, de Tute RM, Davies FE, Bell SE, Drayson MT et al (2015) Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction. Blood 125(12):1932–1935

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Gahrton G, Svensson H, Bjorkstrand B, Apperley J, Carlson K, Cavo M et al (1999) Syngeneic transplantation in multiple myeloma—a case-matched comparison with autologous and allogeneic transplantation. European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 24(7):741–745

    Article  CAS  PubMed  Google Scholar 

  58. Fefer A, Cheever MA, Greenberg PD (1986) Identical-twin (syngeneic) marrow transplantation for hematologic cancers. J Natl Cancer Inst 76(6):1269–1273

    CAS  PubMed  Google Scholar 

  59. Auner HW, Szydlo R, van Biezen A, Iacobelli S, Gahrton G, Milpied N et al (2013) Reduced intensity-conditioned allogeneic stem cell transplantation for multiple myeloma relapsing or progressing after autologous transplantation: a study by the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 48(11):1395–1400

    Article  CAS  PubMed  Google Scholar 

  60. Majolino I, Davoli M, Carnevalli E, Locasciulli A, Di Bartolomeo P, Scime R et al (2007) Reduced intensity conditioning with thiotepa, fludarabine, and melphalan is effective in advanced multiple myeloma. Leuk lymphoma 48(4):759–766

    Article  CAS  PubMed  Google Scholar 

  61. Shimoni A, Hardan I, Ayuk F, Schilling G, Atanackovic D, Zeller W et al (2010) Allogenic hematopoietic stem-cell transplantation with reduced-intensity conditioning in patients with refractory and recurrent multiple myeloma: long-term follow-up. Cancer 116(15):3621–3630

    Article  PubMed  Google Scholar 

  62. Armeson KE, Hill EG, Costa LJ (2013) Tandem autologous vs autologous plus reduced intensity allogeneic transplantation in the upfront management of multiple myeloma: meta-analysis of trials with biological assignment. Bone Marrow Transplant 48(4):562–567

    Article  CAS  PubMed  Google Scholar 

  63. Krishnan A, Pasquini MC, Logan B, Stadtmauer EA, Vesole DH, Alyea E 3rd et al (2011) Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol 12(13):1195–1203

    Article  PubMed  PubMed Central  Google Scholar 

  64. Lokhorst HM, van der Holt B, Cornelissen JJ, Kersten MJ, van Oers M, Raymakers R et al (2012) Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study. Blood 119(26):6219–6225; quiz 399

    Google Scholar 

  65. Garban F, Attal M, Michallet M, Hulin C, Bourhis JH, Yakoub-Agha I et al (2006) Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood 107(9):3474–3480

    Article  CAS  PubMed  Google Scholar 

  66. Bruno B, Rotta M, Patriarca F, Mordini N, Allione B, Carnevale-Schianca F et al (2007) A comparison of allografting with autografting for newly diagnosed myeloma. New Engl J Med 356(11):1110–1120

    Article  CAS  PubMed  Google Scholar 

  67. Martinez-Lopez J, Blade J, Mateos MV, Grande C, Alegre A, Garcia-Larana J et al (2011) Long-term prognostic significance of response in multiple myeloma after stem cell transplantation. Blood 118(3):529–534

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Stem Cell and Allogeneic Transplant, Department of Hematology/Oncology, University of Arkansas for Medical Sciences, Little Rock, AR, USA

    Yogesh S. Jethava & Frits van Rhee

Authors
  1. Yogesh S. Jethava
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Frits van Rhee
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yogesh S. Jethava .

Editor information

Editors and Affiliations

  1. Dept. of Medical Oncolgy/Hematology,, ASST-Spedali Civili di Brescia Dept. of Medical Oncolgy/Hematology,, Brescia, Brescia, Italy

    Aldo M. Roccaro

  2. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA

    Irene M. Ghobrial

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Jethava, Y.S., van Rhee, F. (2016). Transplantation for Multiple Myeloma. In: Roccaro, A., Ghobrial, I. (eds) Plasma Cell Dyscrasias. Cancer Treatment and Research, vol 169. Springer, Cham. https://doi.org/10.1007/978-3-319-40320-5_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-40320-5_13

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-40318-2

  • Online ISBN: 978-3-319-40320-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation